United States Biotechnology & Medical Research

Xenon Pharmaceuticals Inc (XENE)

Track

Track

Xenon Pharmaceuticals experienced significant insider selling activity over the past quarter, totaling approximately 2.66 million dollars. Key executives and directors, including Christopher Kenney and Steven Gannon, executed multiple divestments. These sales occurred following the company's recent earnings report, which showed a modest positive surprise in per-share performance amidst a 17.9 percent stock price increase.
Ticker: XENE Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Xenon Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.2
KENNEY CHRISTOPHER JOHN Chief Medical Officer Officer
Transaction date
Planned sale
Price
228.62
Quantity 87,352 -0.7%
Value US$2,675,677
2.2
KENNEY CHRISTOPHER JOHN Chief Medical Officer Officer
Transaction date
Planned sale
Price
281.68
Quantity 32,949 -29.5%
Value US$2,112,082
2.2
CHRISTOPHER KENNEY Officer Officer
Transaction date
Proposed sale
Price
157.39
Quantity 72,990
Value US$4,250,974
0.7
Gannon, Steven Director of Issuer Non-Executive Director
Transaction date
Sale
Price
64.06
Quantity 8,000 -81.1%
Value US$512,440
3.8
STEVEN GANNON Director Non-Executive Director
Transaction date
Proposed sale
Price
64.06
Quantity 10,000
Value US$640,553
3.8
GANNON STEVEN Non-Executive Director
Transaction date
Sale
Price
64.06
Quantity 10,000 -84.2%
Value US$640,550
2.2
Patou, Gary Director of Issuer Non-Executive Director
Transaction date
Sale
Price
53.14
Quantity 1,322 -4.2%
Value US$70,251
Cannon, Gillian Director of Issuer Non-Executive Director
Transaction date
Sale
Price
53.14
Quantity 1,190 -45.0%
Value US$63,237
2.1
PATOU GARY Non-Executive Director
Transaction date
Planned sale
Price
53.14
Quantity 1,322 -5.0%
Value US$70,251
Cannon Gillian Non-Executive Director
Transaction date
Planned sale
Price
53.14
Quantity 1,190 -45.0%
Value US$63,237
2.1
GARY PATOU Director Non-Executive Director
Transaction date
Proposed sale
Price
52.99
Quantity 1,322
Value US$70,053
2.1
GARY PATOU Director Non-Executive Director
Transaction date
Proposed sale
Price
52.99
Quantity 1,322
Value US$70,053
GILLIAN CANNON Director Non-Executive Director
Transaction date
Proposed sale
Price
52.99
Quantity 1,190
Value US$63,058
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
55.23
Quantity 7,308 -26.8%
Value US$403,584
1.8
Kenney, Christopher John Senior Officer of Issuer Officer
Transaction date
Sale
Price
55.23
Quantity 1,410 -16.6%
Value US$77,867
2.2
DiFabio, Andrea Senior Officer of Issuer Officer
Transaction date
Sale
Price
55.23
Quantity 1,342 -15.5%
Value US$74,112
2.2
KENNEY CHRISTOPHER JOHN Chief Medical Officer Officer
Transaction date
Planned sale
Price
55.23
Quantity 1,410 -16.6%
Value US$77,867
DiFabio Andrea Chief Legal Officer Officer
Transaction date
Planned sale
Price
55.23
Quantity 1,342 -15.5%
Value US$74,112
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
55.23
Quantity 7,308 -26.8%
Value US$403,584
2.2
CHRISTOPHER JOHN KENNEY Officer Officer
Transaction date
Proposed sale
Price
55.22
Quantity 1,410
Value US$77,867
ANDREA DIFABIO Officer Officer
Transaction date
Proposed sale
Price
55.23
Quantity 1,342
Value US$74,112
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
55.22
Quantity 7,308
Value US$403,583
2.2
DiFabio, Andrea Senior Officer of Issuer Officer
Transaction date
Sale
Price
60.11
Quantity 2,607 -34.8%
Value US$156,702
DiFabio Andrea Chief Legal Officer Officer
Transaction date
Planned sale
Price
60.11
Quantity 2,607 -34.8%
Value US$156,702
2.2
KENNEY CHRISTOPHER JOHN Chief Medical Officer Officer
Transaction date
Planned sale
Price
60.11
Quantity 2,771 -36.9%
Value US$166,559
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
60.11
Quantity 11,269 -43.3%
Value US$677,357
ANDREA DIFABIO Officer Officer
Transaction date
Proposed sale
Price
60.11
Quantity 2,607
Value US$156,702
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
60.11
Quantity 11,269
Value US$677,357
2.2
CHRISTOPHER JOHN KENNEY Officer Officer
Transaction date
Proposed sale
Price
60.11
Quantity 2,771
Value US$166,559
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
62.06
Quantity 65,000 -91.5%
Value US$4,033,900
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
60.08
Quantity 61,652 -91.1%
Value CA$3,704,052
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
59.26
Quantity 43,348 -39.1%
Value US$2,568,802
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
61.26
Quantity 2,449 -29.0%
Value US$150,026
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
60.47
Quantity 10,072 -54.4%
Value US$609,054
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
59.50
Quantity 12,479 -40.3%
Value US$742,500
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
60.49
Quantity 21,515 -78.2%
Value US$1,301,442
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
59.88
Quantity 31,694 -53.5%
Value US$1,897,837
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
58.81
Quantity 21,791 -26.9%
Value US$1,281,529
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
62.06
Quantity 65,000 -91.5%
Value US$4,033,900
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
60.08
Quantity 61,652 -91.1%
Value US$3,704,052
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
59.26
Quantity 43,348 -37.4%
Value US$2,568,802
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
61.26
Quantity 2,449 -29.0%
Value US$150,026
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
60.47
Quantity 10,072 -54.4%
Value US$609,054
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
59.50
Quantity 12,479 -40.3%
Value US$742,500
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
60.49
Quantity 21,515 -78.2%
Value US$1,301,442
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
59.88
Quantity 31,694 -53.5%
Value US$1,897,837
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
58.81
Quantity 21,791 -26.9%
Value US$1,281,529
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
60.33
Quantity 270,000
Value US$16,289,196
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
44.93
Quantity 2,062 -25.6%
Value US$92,646
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
44.40
Quantity 37,938 -82.5%
Value US$1,684,447
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
44.43
Quantity 40,000
Value US$1,777,166
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
44.93
Quantity 2,062 -25.6%
Value US$92,646
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
44.40
Quantity 37,938 -82.5%
Value US$1,684,447
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
46.32
Quantity 2,010 -25.1%
Value CA$93,103
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
45.59
Quantity 8,820 -52.4%
Value CA$402,104
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
46.32
Quantity 2,010 -25.1%
Value US$93,103
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
45.59
Quantity 8,820 -52.4%
Value US$402,104
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
45.73
Quantity 10,830
Value US$495,248
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
45.03
Quantity 14,375 -46.1%
Value CA$647,306
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
45.03
Quantity 14,375 -46.1%
Value US$647,306
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
45.03
Quantity 14,375
Value US$647,360
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
45.01
Quantity 97 -0.3%
Value US$4,366
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
45.01
Quantity 97 -0.3%
Value US$4,366
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
45.01
Quantity 97
Value US$4,366
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
40.16
Quantity 25,000 -44.4%
Value US$1,004,000
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
40.16
Quantity 25,000
Value US$1,004,117
2.9
MORTIMER IAN PRESIDENT, CEO & INTERIM CFO Executive Director
Transaction date
Planned sale
Price
40.16
Quantity 25,000 -44.4%
Value US$1,004,000
3.5
SHERRY AULIN Former officer Officer
Transaction date
Proposed sale
Price
37.08
Quantity 2,548
Value US$94,490
0.7
Gannon, Steven Director of Issuer Non-Executive Director
Transaction date
Sale
Price
30.48
Quantity 3 -0.1%
Value US$91
3.8
GANNON STEVEN Non-Executive Director
Transaction date
Sale
Price
30.48
Quantity 3 -0.0%
Value US$91
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
41.07
Quantity 1,149 -3.5%
Value US$47,189
3.3
Mortimer, Ian Charles Senior Officer of Issuer Officer
Transaction date
Sale
Price
40.46
Quantity 15,166 -32.6%
Value US$613,616
2.9
IAN MORTIMER Officer; Director Executive Director
Transaction date
Proposed sale
Price
40.50
Quantity 16,315
Value US$660,823
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
41.07
Quantity 1,149 -3.5%
Value US$47,189
2.9
MORTIMER IAN PRESIDENT & CEO Executive Director
Transaction date
Planned sale
Price
40.46
Quantity 15,166 -32.6%
Value US$613,616
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-31 2026-08-28 PlS Planned sale
2.2
KENNEY CHRISTOPHER JOHN

Chief Medical Officer

Officer
87,352 -0.7%
228.62
US$2,675,677 		87,352 -0.7% 228.62 US$2,675,677
2026-08-31 2026-08-28 PlS Planned sale
2.2
KENNEY CHRISTOPHER JOHN

Chief Medical Officer

Officer
32,949 -29.5%
281.68
US$2,112,082 		32,949 -29.5% 281.68 US$2,112,082
2026-08-28 2026-08-28 PrS Proposed sale
2.2
CHRISTOPHER KENNEY

Officer

Officer
72,990
157.39
US$4,250,974 		72,990 157.39 US$4,250,974
2026-08-14 2026-08-11 S Sale
0.7
Gannon, Steven

Director of Issuer

Non-Executive Director
8,000 -81.1%
64.06
US$512,440 		8,000 -81.1% 64.06 US$512,440
2026-08-13 2026-08-11 PrS Proposed sale
3.8
STEVEN GANNON

Director

Non-Executive Director
10,000
64.06
US$640,553 		10,000 64.06 US$640,553
2026-08-13 2026-08-11 S Sale
3.8
GANNON STEVEN
Non-Executive Director
10,000 -84.2%
64.06
US$640,550 		10,000 -84.2% 64.06 US$640,550
2026-06-09 2026-06-05 S Sale
2.2
Patou, Gary

Director of Issuer

Non-Executive Director
1,322 -4.2%
53.14
US$70,251 		1,322 -4.2% 53.14 US$70,251
2026-06-09 2026-06-05 S Sale
Cannon, Gillian

Director of Issuer

Non-Executive Director
1,190 -45.0%
53.14
US$63,237 		1,190 -45.0% 53.14 US$63,237
2026-06-08 2026-06-05 PlS Planned sale
2.1
PATOU GARY
Non-Executive Director
1,322 -5.0%
53.14
US$70,251 		1,322 -5.0% 53.14 US$70,251
2026-06-08 2026-06-05 PlS Planned sale
Cannon Gillian
Non-Executive Director
1,190 -45.0%
53.14
US$63,237 		1,190 -45.0% 53.14 US$63,237
2026-06-05 2026-06-05 PrS Proposed sale
2.1
GARY PATOU

Director

Non-Executive Director
1,322
52.99
US$70,053 		1,322 52.99 US$70,053
2026-06-05 2026-06-05 PrS Proposed sale
2.1
GARY PATOU

Director

Non-Executive Director
1,322
52.99
US$70,053 		1,322 52.99 US$70,053
2026-06-05 2026-06-05 PrS Proposed sale
GILLIAN CANNON

Director

Non-Executive Director
1,190
52.99
US$63,058 		1,190 52.99 US$63,058
2026-03-16 2026-03-13 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
7,308 -26.8%
55.23
US$403,584 		7,308 -26.8% 55.23 US$403,584
2026-03-16 2026-03-13 S Sale
1.8
Kenney, Christopher John

Senior Officer of Issuer

Officer
1,410 -16.6%
55.23
US$77,867 		1,410 -16.6% 55.23 US$77,867
2026-03-16 2026-03-13 S Sale
2.2
DiFabio, Andrea

Senior Officer of Issuer

Officer
1,342 -15.5%
55.23
US$74,112 		1,342 -15.5% 55.23 US$74,112
2026-03-13 2026-03-13 PlS Planned sale
2.2
KENNEY CHRISTOPHER JOHN

Chief Medical Officer

Officer
1,410 -16.6%
55.23
US$77,867 		1,410 -16.6% 55.23 US$77,867
2026-03-13 2026-03-13 PlS Planned sale
DiFabio Andrea

Chief Legal Officer

Officer
1,342 -15.5%
55.23
US$74,112 		1,342 -15.5% 55.23 US$74,112
2026-03-13 2026-03-13 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
7,308 -26.8%
55.23
US$403,584 		7,308 -26.8% 55.23 US$403,584
2026-03-13 2026-03-13 PrS Proposed sale
2.2
CHRISTOPHER JOHN KENNEY

Officer

Officer
1,410
55.22
US$77,867 		1,410 55.22 US$77,867
2026-03-13 2026-03-13 PrS Proposed sale
ANDREA DIFABIO

Officer

Officer
1,342
55.23
US$74,112 		1,342 55.23 US$74,112
2026-03-13 2026-03-13 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
7,308
55.22
US$403,583 		7,308 55.22 US$403,583
2026-03-13 2026-03-10 S Sale
2.2
DiFabio, Andrea

Senior Officer of Issuer

Officer
2,607 -34.8%
60.11
US$156,702 		2,607 -34.8% 60.11 US$156,702
2026-03-11 2026-03-10 PlS Planned sale
DiFabio Andrea

Chief Legal Officer

Officer
2,607 -34.8%
60.11
US$156,702 		2,607 -34.8% 60.11 US$156,702
2026-03-11 2026-03-10 PlS Planned sale
2.2
KENNEY CHRISTOPHER JOHN

Chief Medical Officer

Officer
2,771 -36.9%
60.11
US$166,559 		2,771 -36.9% 60.11 US$166,559
2026-03-11 2026-03-10 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
11,269 -43.3%
60.11
US$677,357 		11,269 -43.3% 60.11 US$677,357
2026-03-10 2026-03-10 PrS Proposed sale
ANDREA DIFABIO

Officer

Officer
2,607
60.11
US$156,702 		2,607 60.11 US$156,702
2026-03-10 2026-03-10 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
11,269
60.11
US$677,357 		11,269 60.11 US$677,357
2026-03-10 2026-03-10 PrS Proposed sale
2.2
CHRISTOPHER JOHN KENNEY

Officer

Officer
2,771
60.11
US$166,559 		2,771 60.11 US$166,559
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
65,000 -91.5%
62.06
US$4,033,900 		65,000 -91.5% 62.06 US$4,033,900
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
61,652 -91.1%
60.08
CA$3,704,052 		61,652 -91.1% 60.08 CA$3,704,052
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
43,348 -39.1%
59.26
US$2,568,802 		43,348 -39.1% 59.26 US$2,568,802
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
2,449 -29.0%
61.26
US$150,026 		2,449 -29.0% 61.26 US$150,026
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
10,072 -54.4%
60.47
US$609,054 		10,072 -54.4% 60.47 US$609,054
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
12,479 -40.3%
59.50
US$742,500 		12,479 -40.3% 59.50 US$742,500
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
21,515 -78.2%
60.49
US$1,301,442 		21,515 -78.2% 60.49 US$1,301,442
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
31,694 -53.5%
59.88
US$1,897,837 		31,694 -53.5% 59.88 US$1,897,837
2026-03-13 2026-03-09 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
21,791 -26.9%
58.81
US$1,281,529 		21,791 -26.9% 58.81 US$1,281,529
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
65,000 -91.5%
62.06
US$4,033,900 		65,000 -91.5% 62.06 US$4,033,900
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
61,652 -91.1%
60.08
US$3,704,052 		61,652 -91.1% 60.08 US$3,704,052
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
43,348 -37.4%
59.26
US$2,568,802 		43,348 -37.4% 59.26 US$2,568,802
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
2,449 -29.0%
61.26
US$150,026 		2,449 -29.0% 61.26 US$150,026
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
10,072 -54.4%
60.47
US$609,054 		10,072 -54.4% 60.47 US$609,054
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
12,479 -40.3%
59.50
US$742,500 		12,479 -40.3% 59.50 US$742,500
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
21,515 -78.2%
60.49
US$1,301,442 		21,515 -78.2% 60.49 US$1,301,442
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
31,694 -53.5%
59.88
US$1,897,837 		31,694 -53.5% 59.88 US$1,897,837
2026-03-11 2026-03-09 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
21,791 -26.9%
58.81
US$1,281,529 		21,791 -26.9% 58.81 US$1,281,529
2026-03-09 2026-03-09 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
270,000
60.33
US$16,289,196 		270,000 60.33 US$16,289,196
2026-01-06 2026-01-02 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
2,062 -25.6%
44.93
US$92,646 		2,062 -25.6% 44.93 US$92,646
2026-01-06 2026-01-02 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
37,938 -82.5%
44.40
US$1,684,447 		37,938 -82.5% 44.40 US$1,684,447
2026-01-02 2026-01-02 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
40,000
44.43
US$1,777,166 		40,000 44.43 US$1,777,166
2026-01-02 2026-01-02 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
2,062 -25.6%
44.93
US$92,646 		2,062 -25.6% 44.93 US$92,646
2026-01-02 2026-01-02 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
37,938 -82.5%
44.40
US$1,684,447 		37,938 -82.5% 44.40 US$1,684,447
2025-12-10 2025-12-08 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
2,010 -25.1%
46.32
CA$93,103 		2,010 -25.1% 46.32 CA$93,103
2025-12-10 2025-12-08 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
8,820 -52.4%
45.59
CA$402,104 		8,820 -52.4% 45.59 CA$402,104
2025-12-09 2025-12-08 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
2,010 -25.1%
46.32
US$93,103 		2,010 -25.1% 46.32 US$93,103
2025-12-09 2025-12-08 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
8,820 -52.4%
45.59
US$402,104 		8,820 -52.4% 45.59 US$402,104
2025-12-08 2025-12-08 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
10,830
45.73
US$495,248 		10,830 45.73 US$495,248
2025-12-10 2025-12-05 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
14,375 -46.1%
45.03
CA$647,306 		14,375 -46.1% 45.03 CA$647,306
2025-12-09 2025-12-05 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
14,375 -46.1%
45.03
US$647,306 		14,375 -46.1% 45.03 US$647,306
2025-12-05 2025-12-05 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
14,375
45.03
US$647,360 		14,375 45.03 US$647,360
2025-12-04 2025-11-28 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
97 -0.3%
45.01
US$4,366 		97 -0.3% 45.01 US$4,366
2025-12-03 2025-11-28 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
97 -0.3%
45.01
US$4,366 		97 -0.3% 45.01 US$4,366
2025-12-01 2025-11-28 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
97
45.01
US$4,366 		97 45.01 US$4,366
2025-10-02 2025-10-01 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
25,000 -44.4%
40.16
US$1,004,000 		25,000 -44.4% 40.16 US$1,004,000
2025-10-01 2025-10-01 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
25,000
40.16
US$1,004,117 		25,000 40.16 US$1,004,117
2025-10-01 2025-10-01 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT, CEO & INTERIM CFO

Executive Director
25,000 -44.4%
40.16
US$1,004,000 		25,000 -44.4% 40.16 US$1,004,000
2025-09-19 2025-09-19 PrS Proposed sale
3.5
SHERRY AULIN

Former officer

Officer
2,548
37.08
US$94,490 		2,548 37.08 US$94,490
2025-06-10 2025-06-05 S Sale
0.7
Gannon, Steven

Director of Issuer

Non-Executive Director
3 -0.1%
30.48
US$91 		3 -0.1% 30.48 US$91
2025-06-06 2025-06-05 S Sale
3.8
GANNON STEVEN
Non-Executive Director
3 -0.0%
30.48
US$91 		3 -0.0% 30.48 US$91
2025-01-28 2025-01-27 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
1,149 -3.5%
41.07
US$47,189 		1,149 -3.5% 41.07 US$47,189
2025-01-28 2025-01-27 S Sale
3.3
Mortimer, Ian Charles

Senior Officer of Issuer

Officer
15,166 -32.6%
40.46
US$613,616 		15,166 -32.6% 40.46 US$613,616
2025-01-27 2025-01-27 PrS Proposed sale
2.9
IAN MORTIMER

Officer; Director

Executive Director
16,315
40.50
US$660,823 		16,315 40.50 US$660,823
2025-01-27 2025-01-27 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
1,149 -3.5%
41.07
US$47,189 		1,149 -3.5% 41.07 US$47,189
2025-01-27 2025-01-27 PlS Planned sale
2.9
MORTIMER IAN

PRESIDENT & CEO

Executive Director
15,166 -32.6%
40.46
US$613,616 		15,166 -32.6% 40.46 US$613,616
Explore more

More insider trading research around Xenon Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America